- Home
- CDNA vs FRNM Comparison
CDNA vs FRNM Comparison
Compare CDNA & FRNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CDNA | FRNM |
|---|---|---|
| Founded | 1998 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2007 | 2024 |
Fundamental Metrics
Financial Performance| Metric | CDNA | FRNM |
|---|---|---|
| Price | $49.77 | $16.82 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $28.00 | N/A |
| AVG Volume (30 Days) | ★ 970.3K | 892.0K |
| Earning Date | 04-28-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.13 | N/A |
| Revenue | ★ $48,324,000.00 | N/A |
| Revenue This Year | $16.01 | N/A |
| Revenue Next Year | $11.31 | N/A |
| P/E Ratio | $22.94 | ★ N/A |
| Revenue Growth | ★ 18.93 | N/A |
| 52 Week Low | $13.39 | $9.97 |
| 52 Week High | $53.67 | $17.10 |
Technical Indicators
Market Signals| Indicator | CDNA | FRNM |
|---|---|---|
| Relative Strength Index (RSI) | 59.63 | 84.77 |
| Support Level | $44.80 | $9.97 |
| Resistance Level | $49.76 | N/A |
| Average True Range (ATR) | 2.51 | 0.84 |
| MACD | -0.51 | 0.31 |
| Stochastic Oscillator | 45.88 | 99.29 |
Price Performance
Historical ComparisonAbout CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.